- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06198816
Inflow Improve for Deep Vein thrombOsis With Ultrasound acceLerated thrombOlysis and Venoplasty
Inflow Improve for Deep Vein thrombOsis With Ultrasound acceLerated thrombOlysis and Venoplasty: a Monocentric, Observational and Prospective Study.
Aim of the IDOLO study is to investigate clinical efficacy on ultrasound accelerated thrombolysis and venoplasty in patients with post-thrombotic syndrome secondary to chronical femoro-popliteal vein occlusion for previous deep vein Thrombosis (DVT).
At San Raffaele Hospital (Vascular Surgery Department) will be enrolled 50 patients with lower extremity deep vein thrombosis (who have failed conservative treatment) objectively diagnosed with imaging ≥ 6 months; prior persistent deep vein Thrombosis (DVT) at enrollment evaluation and moderate-severe post-thrombotic syndrome at time of procedure
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Domenico Baccellieri, MD
- Phone Number: 7377 +39022643
- Email: baccellieri.domenico@hsr.it
Study Locations
-
-
-
Milano, Italy, 20132
- Recruiting
- San Raffaele Hospital
-
Contact:
- Domenico Baccellieri, MD
- Phone Number: 7377 +39022643
- Email: domenico.baccellieri@hsr.it
-
Contact:
- Elisa Simonini
- Phone Number: 7141 +39022643
- Email: simonini.elisa@hsr.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient admitted in Vascular Surgery Unit, San Raffaele Hospital, Milan
- Patients able to sign specific informed consent for the study.
- Proximal deep vein Thrombosis (iliac vein, common femoral vein, deep femoral vein, and femoral vein) that was objectively diagnosed with duplex imaging and/or venography ≥ 6 months prior to study screening.
- Persistent chronic deep vein Thrombosis causing restrictive flow, as confirmed by imaging, within 60 days prior to the study procedure.
- Failed a minimum of 3 consecutive months of conservative treatment (therapeutic anticoagulation and compression stockings).
- Villalta score ≥8 for the affected limb within 30 days prior to the study procedure
Exclusion Criteria:
- Treated with mechanical thrombectomy within 2 weeks of the study thrombolysis procedure.
- Treated with thrombolysis drugs within 48 hours of the study thrombolytic procedure.
- Life expectancy less than (<) 1 year.
- Body Mass Index (BMI) greater than (>) 40 kilograms/square meter (kg/m^2) or per Investigator's discretion participant is able tolerate the procedure and be compliant with post-procedure increased physical activity.
- No flow in popliteal vein on duplex imaging
- Thrombus extending ≥ 3 centimeters (cm) into the inferior vena cava (IVC). If central venous occlusion, consider computed tomography (CT) or magnetic resonance venography (MRV). For participants with bilateral DVT, it is recommended that central imaging be performed prior to treatment to evaluate the status of the IVC.
- Active bleeding, recent (<3 months) gastrointestinal (GI) bleeding, active peptic ulcer, severe liver dysfunction, and bleeding diathesis.
- Recent (<3 months) internal eye surgery or hemorrhagic retinopathy; recent (<10 days) major surgery, cataract surgery, trauma, cardiopulmonary resuscitation (CPR), obstetrical delivery, or other invasive procedure.
- History of stroke or intracranial/intraspinal bleed, tumor, vascular malformation, or aneurysm.
- Active cancer (metastatic, progressive, or treated within the last 6 months). Participants with non-melanoma primary skin cancers are eligible to participate in the study.
- Hemoglobin <9.0 milligrams/deciliter (mg/dL) within 24 hours prior to the procedure
- International normalized ratio (INR) ≥1.5 nanograms/deciliter (ng/dL) within 24 hours prior to the procedure.
- Platelet count <100,000 cells/cubic millimeter (cells/mm^3) or >700,000 cells/mm^3 within 24 hours prior to the procedure.
- Creatinine outside the normal range for the treating institution and considered clinically significant by the Investigator.
- Uncontrolled hypertension, defined as systolic >175 millimeters of mercury (mmHg) and a diastolic >110 mmHg.
- Use of clopidogrel, ticlopidine, or other thienopyridine antiplatelet drug within 7 days of the study procedure.
- In the judgment of the clinician, the participant is at high risk for catastrophic bleeding.
- Impossibility or refusal to give informed consent
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
DVT patients
|
IDOLO Study investigate clinical efficacy on ultrasound accelerated thrombolysis and venoplasty in patients with post-thrombotic syndrome secondary to chronical femoro-popliteal vein occlusion for previous deep vein Thrombosis (DVT).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Severity Scores
Time Frame: up to 12 months
|
Improvement of Clinical efficacy will be evaluated using the Villalta score
|
up to 12 months
|
Major Bleeding
Time Frame: 72 hours
|
Freedom from Fatal bleeding, Symptomatic bleeding in a critical area or organ,Bleeding causing a fall in hemoglobin level of 20gL
|
72 hours
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Garcia MJ, Sterling KM, Kahn SR, Comerota AJ, Jaff MR, Ouriel K, Weinberg I; ACCESS PTS Investigators. Ultrasound-Accelerated Thrombolysis and Venoplasty for the Treatment of the Postthrombotic Syndrome: Results of the ACCESS PTS Study. J Am Heart Assoc. 2020 Feb 4;9(3):e013398. doi: 10.1161/JAHA.119.013398. Epub 2020 Jan 25.
- Grommes J, Strijkers R, Greiner A, Mahnken AH, Wittens CH. Safety and feasibility of ultrasound-accelerated catheter-directed thrombolysis in deep vein thrombosis. Eur J Vasc Endovasc Surg. 2011 Apr;41(4):526-32. doi: 10.1016/j.ejvs.2010.11.035. Epub 2011 Jan 21.
- Shi Y, Shi W, Chen L, Gu J. A systematic review of ultrasound-accelerated catheter-directed thrombolysis in the treatment of deep vein thrombosis. J Thromb Thrombolysis. 2018 Apr;45(3):440-451. doi: 10.1007/s11239-018-1629-y.
- Dumantepe M, Tarhan IA, Ozler A. Treatment of chronic deep vein thrombosis using ultrasound accelerated catheter-directed thrombolysis. Eur J Vasc Endovasc Surg. 2013 Sep;46(3):366-71. doi: 10.1016/j.ejvs.2013.05.019. Epub 2013 Jun 25.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IDOLO Study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post-Thrombotic Syndrome of Both Legs
-
Massachusetts General HospitalActive, not recruitingDeep Venous Thrombosis | Post-thrombotic SyndromeUnited States
-
University of ZurichJH Rahn Foundation, ZurichCompletedChronic Venous Insufficiency | Post-thrombotic SyndromeSwitzerland
-
Sir Mortimer B. Davis - Jewish General HospitalActive, not recruiting
-
Bama GeVe, S.L.U.TerminatedPost-thrombotic SyndromeSpain
-
University of Colorado, DenverNational Heart, Lung, and Blood Institute (NHLBI); Genentech, Inc.; RTI International and other collaboratorsWithdrawnVenous Thrombosis | Deep Vein Thrombosis | Post-Thrombotic Syndrome
-
Boston Scientific CorporationEKOS CorporationCompletedDeep Vein Thrombosis | Post-thrombotic SyndromeUnited States
-
Inari MedicalRecruitingVenous Thromboembolism | Deep Venous Thrombosis | Post-Thrombotic SyndromeUnited States, Germany, Finland, Switzerland, United Kingdom
-
Khanh NguyenRecruitingDeep Vein Thrombosis Leg | Post-thrombotic SyndromeUnited States
-
Laboratoires InnotheraUniversity Hospital, Grenoble; FloralisCompletedDeep Vein Thrombosis | Post-thrombotic SyndromeFrance
-
Sir Mortimer B. Davis - Jewish General HospitalCanadian Institutes of Health Research (CIHR); Heart and Stroke Foundation... and other collaboratorsWithdrawnDeep Vein Thrombosis | Postphlebitic Syndrome | Post-Thrombotic SyndromeCanada
Clinical Trials on ultrasound accelerated thrombolysis and venoplasty
-
Emory UniversityCompletedCardiovascular DiseasesUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Multiple Sclerosis Society of...Completed
-
Niguarda HospitalRecruiting
-
Northwell HealthCompletedThromboembolism | Pulmonary Hypertension | Pulmonary Embolism | Right Ventricular DysfunctionUnited States
-
University Hospital Inselspital, BerneUniversity of Zurich; University Hospital, Geneva; University Hospital, Basel... and other collaboratorsCompletedIschemic StrokeSwitzerland
-
University of Toledo Health Science CampusWithdrawnPost Thrombotic Syndrome | Deep Venous ThrombosisUnited States
-
Second Hospital of Jilin UniversityUnknownAcute ST Segment Elevation Myocardial InfarctionChina
-
National Institute of Cardiovascular Diseases,...East Slovakia Institute of Cardiovascular Diseases in Košice, Slovakia; Central...CompletedAcute Deep Venous ThrombosisSlovakia
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAnatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage 0 Breast Cancer AJCC v8 | HER2-Negative Breast Carcinoma | Estrogen Receptor-Positive Breast CarcinomaUnited States
-
Zhengzhou YuanRecruiting